Treatment of medication overuse headache: Effect and predictors after 1 year-A randomized controlled trial
- PMID: 34325483
- DOI: 10.1111/head.14177
Treatment of medication overuse headache: Effect and predictors after 1 year-A randomized controlled trial
Abstract
Background: Combined withdrawal and early preventive medication was the most effective treatment for medication overuse headache (MOH) within the first 6 months in a previous study, but results from a longer follow-up period are lacking.
Objective: (1) To measure the efficacy at 1 year of three different treatment approaches to MOH; (2) to compare withdrawal and early preventives (W+P), preventives with potential withdrawal therapy after 6 months (P+pW), and withdrawal with delayed potential preventives (W+pP); and (3) to identify predictors of chronic headache after 1 year.
Methods: Patients with MOH and migraine and/or tension-type headache were randomly assigned to one of the three outpatient treatments. Headache calendar and questionnaires were filled out. Primary outcome was a reduction in headache days/month after 1 year.
Results: Of 120 patients, 96 completed 1-year follow-up, and all were included in our analyses. Overall headache days/month were reduced from 24.6 (23.4-25.8) to 15.0 (13.0-17.0) (p < 0.0001), and only 11/96 patients (11%) relapsed. Reduction in monthly headache days was 10.3 days (95% CI: 6.7-13.9) in the W+P group, 10.8 days (95% CI: 7.6-14) in the P+pW group, and 7.9 days (95% CI: 5.1-10.7) in the W+pP group. No significant differences in treatment effect were seen between the three groups (p = 0.377). After 1 year, 39/96 (41%) had chronic headache. Predictors of chronic headache after 1 year were higher headache frequency (aOR 1.19; 1.09-1.31), more days with acute medication (aOR 1.11; 1.03-1.19), higher pain intensity (aOR 1.04; 1.01-1.08), and depression (aOR 4.7; 1.38-18.95), whereas higher self-rated health (aOR 0.61; 0.36-0.97) and high caffeine consumption (aOR 0.40; 0.16-0.96) were predictors of a lower risk of chronic headache. No adverse events were reported.
Conclusions: All treatment strategies proved effective in treating MOH with a low relapse rate. The W+P strategy leads to the fastest effect, confirming earlier treatment recommendations. Identification of predictors for chronic headache may help identify more complex patients.
Keywords: medication overuse headache; predictors; preventive medication; withdrawal.
© 2021 American Headache Society.
Similar articles
-
Comparison of 3 Treatment Strategies for Medication Overuse Headache: A Randomized Clinical Trial.JAMA Neurol. 2020 Sep 1;77(9):1069-1078. doi: 10.1001/jamaneurol.2020.1179. JAMA Neurol. 2020. PMID: 32453406 Free PMC article. Clinical Trial.
-
Management of medication overuse headache: 1-year randomized multicentre open-label trial.Cephalalgia. 2009 Feb;29(2):221-32. doi: 10.1111/j.1468-2982.2008.01711.x. Epub 2008 Sep 24. Cephalalgia. 2009. PMID: 18823363 Clinical Trial.
-
Complete withdrawal is the most feasible treatment for medication-overuse headache: A randomized controlled open-label trial.Eur J Pain. 2019 Jul;23(6):1162-1170. doi: 10.1002/ejp.1383. Epub 2019 Mar 15. Eur J Pain. 2019. PMID: 30793412 Clinical Trial.
-
[Medication-overuse headache].MMW Fortschr Med. 2006 Aug 31;148(35-36):37-8. doi: 10.1007/BF03364717. MMW Fortschr Med. 2006. PMID: 16995362 Review. German.
-
The Many Faces of Medication-Overuse Headache in Clinical Practice.Headache. 2020 May;60(5):1021-1036. doi: 10.1111/head.13785. Epub 2020 Mar 30. Headache. 2020. PMID: 32232847 Review.
Cited by
-
Medication-Overuse Headache: Update on Management.Life (Basel). 2024 Sep 11;14(9):1146. doi: 10.3390/life14091146. Life (Basel). 2024. PMID: 39337929 Free PMC article. Review.
-
Baseline demographics and disease characteristics of patients with episodic or chronic cluster headache: data from two phase 3 randomized clinical trials in Europe and North America.Front Neurol. 2023 Dec 15;14:1293163. doi: 10.3389/fneur.2023.1293163. eCollection 2023. Front Neurol. 2023. PMID: 38162453 Free PMC article.
-
Diamine Oxidase Interactions with Anti-Inflammatory and Anti-Migraine Medicines in the Treatment of Migraine.J Clin Med. 2023 Dec 4;12(23):7502. doi: 10.3390/jcm12237502. J Clin Med. 2023. PMID: 38068554 Free PMC article.
-
Medication Overuse Headache: an Updated Review and Clinical Recommendations on Management.Curr Neurol Neurosci Rep. 2023 Jul;23(7):389-398. doi: 10.1007/s11910-023-01278-y. Epub 2023 Jun 5. Curr Neurol Neurosci Rep. 2023. PMID: 37271793 Review.
-
Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study.J Headache Pain. 2022 Sep 6;23(1):115. doi: 10.1186/s10194-022-01482-0. J Headache Pain. 2022. PMID: 36068494 Free PMC article. Clinical Trial.
References
REFERENCES
-
- Olesen J, Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211.
-
- Vos T, Abajobir AA, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211-1259.
-
- Vos T, Allen C, Arora M, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545-1602.
-
- Diener H-C, Dodick D, Evers S, et al. Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol. 2019;18(9):891-902.
-
- Lipton RB. Risk factors for and management of medication-overuse headache. Continuum. 2015;21:1118-1131.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
